Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas von Elkrief, Arielle, Makhnin, Alex, Moses, Khadeja A, Ahn, Linda S, Preeshagul, Isabel R, Iqbal, Afsheen N, Hayes, Sara A, Plodkowski, Andrew J, Paik, Paul K, Ladanyi, Marc, Kris, Mark G, Riely, Gregory J, Michor, Franziska, Yu, Helena A

Volltext